← TAKEDA PHARMACEUTICAL CO LTD

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 TTM
Total Revenue $1.7t
$1.8t +2.22%
$2.1t +18.45%
$3.3t +56.93%
$3.2t -2.84%
$3.6t +11.61%
$4.0t +12.85%
$4.3t +5.87%
$4.6t +7.45%
$4.5t -1.66%
$4.6t +2.51%
Revenue From Interest — — $6.6b $11.2b $1.8b $4.6b $5.5b $11.3b $19.6b $16.9b —
Cost of Goods and Services Sold ($558.8b)
($495.9b) +11.25%
$659.7b +233.02%
$1.1t +65.19%
$994.3b -8.76%
$1.1t +11.32%
$1.2t +12.40%
$1.4t +14.68%
$1.6t +10.76%
($1.6t) -199.45%
$1.6t +201.40%
Cost of sales ($558.8b)
($495.9b) +11.25%
($659.7b) -33.02%
($1.1t) -65.19%
($994.3b) +8.76%
($1.1t) -11.32%
($1.2t) -12.40%
($1.4t) -14.68%
($1.6t) -10.76%
($1.6t) +0.55%
$1.6t +201.40%
Cost Of Revenue — — — — — — $1.2t
$1.4t +14.68%
$1.6t +10.76%
$1.6t -0.55%
$1.6t +1.40%
Reconciled Cost Of Revenue — — — — — — $1.1t
$1.4t +20.38%
$1.5t +8.24%
$1.5t +1.50%
$1.6t +7.38%
Gross Profit $1.2t
$1.3t +8.63%
$1.4t +12.78%
$2.2t +53.14%
$2.2t +0.09%
$2.5t +11.74%
$2.8t +13.05%
$2.8t +1.93%
$3.0t +5.79%
$2.9t -2.24%
$3.0t +3.11%
Net Interest Income — — — — — — ($123.4b)
($140.5b) -13.84%
($160.6b) -14.30%
($143.8b) +10.45%
($149.6b) -4.06%
Research and development $312.3b $325.4b $368.3b $492.4b $455.8b $526.1b $633.3b $729.9b $730.2b $675.9b $699.4b
Restructuring And Mergern Acquisition — — — — — — $63.2b $102.1b $127.5b $71.8b $71.8b
Operating expenses:
Other operating expenses ($72.9b) ($126.6b) ($103.2b) ($248.7b) ($258.9b) ($159.1b) ($145.2b) ($206.5b) ($206.7b) ($559.0b) —
Other operating income $143.5b $169.4b $159.9b $60.2b $318.0b $43.1b $25.4b $19.4b $26.2b $24.7b —
Interest Expense — — $48.2b $149.0b $130.8b $122.4b $117.0b $119.5b $137.3b $148.1b $104.8b
Interest Expense On Lease Liabilities — — — $11.8b $12.1b $13.9b $16.6b $20.8b $24.5b — $104.8b
Interest Income — — $6.6b $11.2b $1.8b $4.6b $5.5b $11.3b $19.6b $16.9b ($32.3b)
Net Non Operating Interest Income Expense — — — — — — ($123.4b) ($140.5b) ($160.6b) ($143.8b) ($149.6b)
Gain On Sale Of Business — — — — — — $6.8b $7.8b $10.2b $18.3b $18.3b
Gain On Sale Of PPE — — — — — — $2.1b $144.0m $363.0m $165.0m $165.0m
Gain On Sale Of Security — — — — — — $6.4b ($9.1b) $7.6b $6.1b $6.1b
Other Income $143.5b $169.4b $159.9b $60.2b $318.0b $43.1b $25.4b $19.4b $26.2b $24.7b —
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method ($1.5b) ($32.2b) ($43.6b) ($24.0b) $76.0m ($15.4b) ($8.6b) $6.5b ($4.0b) ($2.2b) —
Share of profit (loss) of investments accounted for using the equity method ($1.5b) ($32.2b) ($43.6b) ($24.0b) $76.0m ($15.4b) ($8.6b) $6.5b ($4.0b) ($2.2b) —
Other Income Expense — — — — — — ($89.3b) ($116.6b) ($130.7b) ($463.0b) ($462.0b)
Pre-Tax Income $143.3b $217.2b $94.9b ($60.8b) $366.2b $302.6b $375.1b $52.8b $175.1b ($142.4b) ($130.3b)
Current Tax Expense (Income) — — $61.6b $238.9b $132.0b $208.5b $246.6b $107.3b $138.1b — —
Deferred Tax Expense (Income) — — ($75.7b) ($343.9b) ($141.9b) ($136.1b) ($188.5b) ($198.8b) ($71.1b) — —
Income Tax Expense Continuing Operations $27.8b $30.5b ($14.1b) ($105.0b) ($9.9b) $72.4b $58.1b ($91.4b) $66.9b $9.8b $32.9b
Net Income From Continuing And Discontinued Operation — — $109.1b $44.2b $376.0b $230.1b $317.0b $144.1b $107.9b ($152.4b) ($163.4b)
Net Income Continuous Operations $115.5b $186.7b $109.0b $44.3b $376.2b $230.2b $317.0b $144.2b $108.1b ($152.1b) ($163.1b)
Basic Earnings (Loss) Per Share $147.15 $239.35 $113.50 $28.41 $240.72 $147.14 $204.29 $92.09 $68.36 ($96.75) ($52.25)
Diluted Earnings (Loss) Per Share $146.26 $237.56 $112.86 $28.25 $238.96 $145.87 $201.94 $91.16 $67.23 ($96.75) ($52.25)
Basic Average Shares — — — — — — $3.1b $3.1b $3.2b $3.2b $3.2b
Diluted Average Shares — — — — — — $3.1b $3.2b $3.2b $3.2b $3.2b
Additional Financial Items
Applicable Tax Rate — — $0 $0 $0 $0 $0 $0 $0 — —
Average Effective Tax Rate — — ($0) $2 — — — — — — —
Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss — — $1.4b $50.7b $11.4b $479.0m $2.3b $7.5b $4.5b — $612.8b
Finance Income $12.3b $39.5b $16.8b $27.8b $105.5b $23.7b $62.9b $52.1b $46.5b $211.2b —
Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill — — $8.7b $48.1b $16.6b $67.7b $57.3b $169.4b $95.6b — —
Profit Loss Attributable To Noncontrolling Interests — — ($112.0m) $49.0m $166.0m $107.0m $21.0m $130.0m $215.0m — —
Profit Loss Attributable To Owners Of Parent — — $109.1b $44.2b $376.0b $230.1b $317.0b $144.1b $107.9b ($152.4b) —
Profit Loss Before Tax $143.3b $217.2b $94.9b ($60.8b) $366.2b $302.6b $375.1b $52.8b $175.1b ($142.4b) —
Profit Loss From Operating Activities $155.9b $241.8b $205.0b $100.4b $509.3b $460.8b $490.5b $214.1b $342.6b $6.2b —
Amortization and impairment losses on intangible assets associated with products ($156.7b) ($122.1b) ($203.4b) ($455.4b) ($421.9b) ($472.9b) ($542.4b) ($652.1b) ($643.2b) ($633.5b) —
Operating profit $155.9b
$241.8b +55.13%
$205.0b -15.23%
$100.4b -51.01%
$509.3b +407.20%
$460.8b -9.51%
$490.5b +6.44%
$214.1b -56.36%
$342.6b +60.03%
$6.2b -98.19%
—
Net profit (loss) for the year $115.5b $186.7b $109.0b $44.3b $376.2b $230.2b $317.0b $144.2b $108.1b ($152.1b) —
Owners of the Company $114.9b $186.9b $109.1b ($199.6b) $376.0b $230.1b $317.0b $144.1b $107.9b ($152.4b) —
Non-controlling interests $573.0m ($178.0m) ($112.0m) $150.0m $166.0m $107.0m $21.0m $130.0m $215.0m $264.0m —
Amortization — — — — — — $542.4b $652.1b $643.2b $633.5b $612.8b
Diluted EPS — — — — — — $100.97 $45.58 $33.62 ($48.38) ($52.25)
Diluted NI Availto Com Stockholders — — $109.1b $44.2b $376.0b $230.1b $317.0b $144.1b $107.9b ($152.4b) ($163.4b)
Earnings From Equity Interest — — — — — — $13.8b $6.5b ($4.0b) ($2.2b) ($1.1b)
Minority Interests — — — — — — ($21.0m) ($130.0m) ($215.0m) ($264.0m) ($288.0m)
Normalized EBITDA — — — — — — $1.3t $1.0t $1.2t $1.2t $587.4b
Normalized Income — — — — — — $404.2b $238.6b $186.2b $124.1b $113.1b
Other Special Charges — — — — — — $24.6b $18.2b $10.6b $412.2b —
Reconciled Depreciation — — $272.4b $583.6b $559.7b $583.2b $664.4b $728.0b $761.4b $721.1b $612.8b
Selling General And Administration $619.1b $628.1b $717.6b $964.7b $875.7b $886.4b $997.3b $1.1t $1.1t $1.1t —
Special Income Charges — — — — — — ($109.6b) ($114.0b) ($134.3b) ($467.0b) ($467.0b)
Tax Effect Of Unusual Items — — — — — — ($16.0b) ($28.6b) ($48.5b) ($184.3b) ($184.3b)
Tax Provision $27.8b $30.5b ($14.1b) ($105.0b) ($9.9b) $72.4b $58.1b ($91.4b) $66.9b $9.8b $32.9b
Tax Rate For Calcs — — — — — — $0 $0 $0 $0 $0
Write Off — — — — — — $30.6b $1.7b $6.8b $1.4b $1.4b
Administrative Expense $619.1b $628.1b $717.6b $964.7b $875.7b $886.4b $997.3b $1.1t $1.1t $1.1t —
Depreciation And Amortisation Expense — — $272.4b $583.6b $559.7b $583.2b $664.4b $728.0b $761.4b $721.1b $612.8b
Donations And Subsidies Expense — — $3.6b $8.5b $8.4b $8.3b $7.7b $7.0b $7.7b — —
Expense Relating To Leases Of Low-Value Assets For Which Recognition Exemption Has Been Used — — — $1.6b $1.2b $1.3b $1.3b $887.0m $493.0m — —
Expense Relating To Short-Term Leases For Which Recognition Exemption Has Been Used — — — $5.8b $4.8b $4.5b $4.5b $4.3b $4.2b — —
Expense Relating To Variable Lease Payments Not Included In Measurement Of Lease Liabilities — — — $8.2b $6.3b $4.0b $4.8b $11.0b $11.2b — —
Finance Costs — — $83.3b $165.0b $248.6b $166.6b $169.7b $219.8b $210.1b — —
Other Employee Expense — — $93.7b $157.7b $163.4b $187.4b $237.9b $274.1b $266.5b — —
Other Finance Cost — — $3.9b $9.6b $16.9b $19.3b $19.4b $34.1b $49.7b — —
Postemployment Benefit Expense Defined Benefit Plans — — $11.4b $16.3b $8.0b — — — — — —
Postemployment Benefit Expense Defined Contribution Plans — — $21.1b $25.1b $34.1b $37.3b $46.4b $60.5b $52.7b — —
Finance expenses ($23.2b) ($31.9b) ($83.3b) ($165.0b) ($248.6b) ($166.6b) ($169.7b) ($219.8b) ($210.1b) ($357.6b) —
Operating Expense — — — — — — $2.2t $2.5t $2.5t $2.5t $2.5t
Net Foreign Exchange Loss — — $0 $0 $97.3b $1.8b $14.2b $44.7b $7.2b — —
Total Unusual Items — — — — — — ($103.1b) ($123.1b) ($126.7b) ($460.9b) ($460.9b)
Total Expenses — — — — — — $3.4t $4.0t $4.1t $4.0t $4.1t
Total Other Finance Cost — — — — — — $11.9b $32.2b $42.9b $12.5b $12.5b

Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.